Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study

CONCLUSION: COVID vaccination status and comorbidities are significant predictors of outcomes after casirivimab-imdevimab treatment. Despite having higher comorbidities, patients who were fully vaccinated at the time of casirivimab-imdevimab infusion had a lower length of hospitalization and reduced 28-day COVID ED visits or hospitalizations. Future trials should also compare outcomes based on the patient's vaccination status.PMID:37451874 | DOI:10.1016/j.vaccine.2023.07.011

Source: Vaccine - July 14, 2023 Category: Allergy & Immunology Authors: Pankaj Agrawal Dushyant Damania Attila Cseh John Grab Laura Strom Brianna Frank Dhruv Patel Griffin Clyatt Source Type: research